Stock listing

Celldex Therapeutics, Inc.

Selected listing: TCE2 · SWB · EUR · DE

Celldex Therapeutics, Inc. (Stuttgart:TCE2), Health Technology. Latest release Sep 22, 2026: Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1…

TCE2:SWBEURDEUpdated October 2, 2026

Ticker: Stuttgart:TCE2
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: Stuttgart
Currency: EUR

About Celldex Therapeutics, Inc.

The company focuses on developing innovative therapies for cancer and other serious diseases. Celldex is committed to advancing its pipeline of products to improve patient outcomes.

Latest news from Celldex Therapeutics, Inc.

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

September 22, 2026

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

August 6, 2026

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

July 21, 2026

Celldex Announces Planned Transition of Chief Financial Officer

July 15, 2026

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

June 14, 2026

All Celldex Therapeutics, Inc. news →

Events

Replays

Celldex Therapeutics, Inc. (CLDX) Q1 2025 Earnings Call
Thu, Jun 12, 2025 · 06:00 PM ET
Watch
Celldex Therapeutics, Inc. (CLDX) Q4 2021 Earnings Call
Mon, Feb 28, 2022 · 04:30 PM ET
Watch

Research Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. company profile

View the public company page for Celldex Therapeutics, Inc. on 6ix.

Celldex Therapeutics, Inc. news

Read company news and market updates connected to Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. investor events

Find investor webinars, events, and replay context for Celldex Therapeutics, Inc..